Accurate identification of Alzheimer's disease (AD) is still of major clinical importance considering the current lack of noninvasive and low-cost diagnostic approaches. Detection of early stage AD is particularly desirable as it would allow early intervention or recruitment of patients into clinical trials. There is also an unmet need for discrimination of AD from dementia with Lewy bodies (DLB), as many cases of the latter are misdiagnosed as AD. Biomarkers based on a simple blood test would be useful in research and clinical practice. Raman spectroscopy has been implemented to analyze blood plasma of a cohort that consisted of early stage AD, late-stage AD, DLB, and healthy controls. Classification algorithms achieved high accuracy for the different groups: early stage AD vs healthy with 84% sensitivity, 86% specificity; late-stage AD vs healthy with 84% sensitivity, 77% specificity; DLB vs healthy with 83% sensitivity, 87% specificity; early-stage AD vs DLB with 81% sensitivity, 88% specificity; late-stage AD vs DLB with 90% sensitivity, 93% specificity; and lastly, early-stage AD vs late-stage AD 66% sensitivity and 83% specificity. G-score values were also estimated between 74% and 91%, demonstrating that the overall performance of the classification model was satisfactory. The wavenumbers responsible for differentiation were assigned to important biomolecules, which can serve as a panel of biomarkers. These results suggest a cost-effective, blood-based test for neurodegeneration in dementias.

中文翻译：

---

拉曼光谱法诊断血液中路易体的阿尔茨海默氏病和痴呆症。

考虑到当前缺乏无创且低成本的诊断方法，准确识别阿尔茨海默氏病（AD）仍然具有重要的临床意义。早期AD的检测是特别可取的，因为它将允许早期干预或招募患者进入临床试验。由于路易体（DLB）导致许多人被误诊为AD，因此也存在歧视AD与痴呆症的需求。基于简单血液测试的生物标志物将在研究和临床实践中有用。拉曼光谱法已被用于分析队列的血浆，该队列包括早期AD，晚期AD，DLB和健康对照。分类算法在不同组中实现了较高的准确性：早期AD与健康组的敏感性为84％，特异性为86％；晚期AD vs健康，敏感性为84％，特异性为77％；DLB vs健康，敏感性为83％，特异性为87％；早期AD与DLB的敏感性为81％，特异性为88％；晚期AD与DLB的敏感性为90％，特异性为93％；最后，早期AD与晚期AD的敏感性为66％，特异性为83％。G值也估计在74％到91％之间，这表明分类模型的总体性能令人满意。负责分化的波数被分配给重要的生物分子，这些生物分子可以作为一组生物标志物。这些结果表明，对老年痴呆症的神经退行性疾病进行基于血液的成本合算的测试。晚期AD与DLB的敏感性为90％，特异性为93％；最后，早期AD与晚期AD的敏感性为66％，特异性为83％。G值也估计在74％到91％之间，这表明分类模型的总体性能令人满意。负责分化的波数被分配给重要的生物分子，这些生物分子可以作为一组生物标志物。这些结果表明，对老年痴呆症的神经退行性疾病进行基于血液的成本合算的测试。晚期AD与DLB的敏感性为90％，特异性为93％；最后，早期AD与晚期AD的敏感性为66％，特异性为83％。G值也估计在74％到91％之间，这表明分类模型的总体性能令人满意。负责分化的波数被分配给重要的生物分子，这些生物分子可以作为一组生物标志物。这些结果表明，对老年痴呆症的神经退行性疾病进行基于血液的成本合算的测试。负责分化的波数被分配给重要的生物分子，这些生物分子可以作为一组生物标志物。这些结果表明，对老年痴呆症的神经退行性疾病进行基于血液的成本合算的测试。负责分化的波数被分配给重要的生物分子，这些生物分子可以作为一组生物标志物。这些结果表明，对老年痴呆症的神经退行性疾病进行基于血液的成本合算的测试。